Arrayit Diagnostics to be Stand-Alone Company | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Arrayit today announced it is spinning out its majority-owned subsidiary Arrayit Diagnostics, which it expects to be listed on the Over-the-Counter Bulletin Board.

Arrayit will distribute its 78.18 percent interest in Arrayit Diagnostics as a stock dividend to its existing shareholders. The dividend distribution date and further details will be announced in the first quarter of 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.